Oxyntomodulin suppresses appetite and reduces food intake in humans
Oxyntomodulin suppresses appetite and reduces food intake in humans
复制标题
DOI：
10.1210/jc.2003-030421
复制
发表时间：
2003-10-01
影响因子：
5.8
通讯作者：
Bloom, SR
中科院分区：
文献类型：
--
作者：
Cohen, MA;Ellis, SM;Bloom, SR
胃泌酸调节素（OXM）在餐后与能量摄入成比例地从肠道释放，并且在与厌食症相关的几种病症中OXM的循环水平升高。中枢注射OXM可减少啮齿类动物的食物摄入和体重增加，表明OXM向下丘脑食欲调节回路发出食物摄入信号。在一项随机、双盲、安慰剂对照、交叉研究中，我们研究了静脉注射OXM（3.0 pmol/kg.min）对13名健康受试者（体重指数，22.5 ± 0.9 kg/m2）食欲和食物摄入的影响。输注OXM显著降低了自助餐时的随意能量摄入（平均降低，19.3 +/- 5.6%; P < 0.01），并导致饥饿评分显著降低。此外，输注OXM显著降低了累积的12小时能量摄入（平均降低11.3 ± 6.2%; P < 0.05）。OXM不会引起恶心或影响食物的适口性。餐前食欲刺激激素ghrelin的水平被OXM显著抑制（平均降低，餐后降低的44 +/- 10%; P < 0.0001）。与胃肠道疾病相关的内源性OXM水平升高可能导致厌食症。
Oxyntomodulin (OXM) is released from the gut postprandially, in proportion to energy intake, and circulating levels of OXM are elevated in several conditions associated with anorexia. Central injection of OXM reduces food intake and weight gain in rodents, suggesting that OXM signals food ingestion to hypothalamic appetite-regulating circuits. We investigated the effect of iv OXM (3.0 pmol/kg.min) on appetite and food intake in 13 healthy subjects (body mass index, 22.5 +/- 0.9 kg/m(2)) in a randomized, double-blind, placebo-controlled, cross-over study. Infusion of OXM significantly reduced ad libitum energy intake at a buffet meal (mean decrease, 19.3 +/- 5.6%; P < 0.01) and caused a significant reduction in scores for hunger. In addition, cumulative 12-h energy intake was significantly reduced by infusion of OXM (mean decrease, 11.3 +/- 6.2%; P < 0.05). OXM did not cause nausea or affect food palatability. Preprandial levels of the appetite-stimulatory hormone, ghrelin, were significantly suppressed by OXM (mean reduction, 44 +/- 10% of postprandial decrease; P < 0.0001). Elevated levels of endogenous OXM associated with disorders of the gastrointestinal tract may contribute to anorexia.